Last update Dec. 20, 2021
Very Low Risk
Long-acting agonist of the glucagon-like peptide receptor type 1 (GLP-1) that stimulates the endogenous secretion of insulin and decreases that of glucagon. Used in type 2 diabetes in combination with other oral anti-diabetics, especially metformin. Subcutaneous administration once a week. There is risk of hypoglycaemia even in monotherapy.
Since the last update, we have not found published data on its excretion in breast milk.
Its high molecular weight make it very unlikely that significant amounts will pass into breast milk. (Serrano 2014)
Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed (Serrano 2014). This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM